Tekla Capital Management’s TScan Therapeutics TCRX Stock Holding History

Tekla Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$500K	Hold	200,000	–	–	0.02%	142
2023 Q1	$420K	Hold	200,000	–	–	0.02%	156
2022 Q4	$326K	Hold	200,000	–	–	0.01%	154
2022 Q3	$610K	Hold	200,000	–	–	0.03%	142
2022 Q2	$629K	Hold	200,000	–	–	0.02%	143
2022 Q1	$560K	Hold	200,000	–	–	0.02%	159
2021 Q4	$900K	Hold	200,000	–	–	0.03%	148
2021 Q3	$1.67M	Buy	+200,000	New	+$1.85M	0.05%	140

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Tekla Capital Management's TCRX Position: Q2 2023 in Review

Tekla Capital Management held its TScan Therapeutics (TCRX) position steady in Q2 2023 at 200,000 shares worth $500K. The position accounts for 0.02% of the portfolio, ranked #142.

Tekla Capital Management first reported a position in TCRX in Q3 2021 and has held it in 8 quarters since. The position peaked at $1.67M in Q3 2021. 28 funds tracked by Wall St. Rank hold TCRX as of Q2 2023.

Tekla Capital Management held 200,000 shares of TScan Therapeutics worth $500K as of Q2 2023.
Tekla Capital Management left its TScan Therapeutics share count unchanged in Q2 2023.
TScan Therapeutics made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #142 holding.
Tekla Capital Management first reported a position in TScan Therapeutics in Q3 2021 and has held it in 8 quarters since.
Tekla Capital Management's TScan Therapeutics position peaked at $1.67M in Q3 2021.
28 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.